/
Not financial advice. Analytical data for research only.
Intrinsiqq is a Netherlands-based company operating in Rotterdam, KvK 73238007.
We are a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for patients with cancer. We leverage our team s deep expertise in chemistry and structure-based drug design to develop innovative small molecules that are designed with the aim to overcome the limitations of existing therapies for clinically proven kinase targets.
$123.96
+$0.00 (+0.00%)
Price from 61 days ago
ROIC dropped from -25.02% to -28.24%, capital efficiency is deteriorating.
Based on TTM earnings · Diluted shares
Profitability & Returns
Revenue
N/A
Net Income (TTM)
-$450M
▼ -63.1% YoY
Op. Margin
—
ROIC
-32.96%
▼ -3.2pp YoY
Cash Flow & Balance Sheet
FCF
N/A
Op. Cash Flow (TTM)
-$313M
▼ -48.7% YoY
Net Debt
-$1.29B
Net Cash Position
Cash & Equiv.
$1.29B
Continue Research
SourceComputed from the 10-Q filed 7 May 2026, covering the period ending 31 Mar 2026, as reported to the SEC. Data last refreshed 4 Sept 2026. How this is calculated.
Price from market data, last close as of 21 Jul 2026. Fiscal year ends Dec. Sector medians are approximate S&P 500 benchmarks and update periodically.